InnovaRx Innova Health Strategies

G23.1

Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 9 never code together
G23code
Excludes2
  • multi-system degeneration of the autonomic nervous system (G90.3)G90.3
G00-G99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 1
G23.1code
Inclusion terms
  • Progressive supranuclear palsy
Index entries leading here 5
  • Palsy G83.9
    • bulbar (progressive) (chronic) G12.22
      • supranuclear (progressive) G23.1
    • progressive supranuclear G23.1
  • Ophthalmoplegia — see also Strabismus, paralytic
    • supranuclear, progressive G23.1
  • Paralysis, paralytic (complete) (incomplete) G83.9
    • progressive (atrophic) (bulbar) (spinal) G12.22
    • supranuclear (progressive) G23.1
  • Steele-Richardson-Olszewski disease or syndrome G23.1
  • Willige-Hunt disease or syndrome G23.1
Alongside this code 5 same parent — G23
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC78 CMS28HCC199 ESRD21HCC78 ESRD24HCC78 RX08HCC161

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
G23
Block
G20-G26
Siblings
5

Present FY2024–FY2027.